Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 501-510 of 9364

Page
per page
  1. Ranolazine 2HCl
    A5300 Ranolazine 2HCl
    Summary: Partial fatty acid oxidation inhibitor
      ≥20.25 mg/mL
  2. Zonisamide
    A5354 Zonisamide
    Target: Voltage-gated Sodium (NaV) Channels|Voltage-gated Calcium Channels (CaV)|Carbonic Anhydrases|Calcium-Activated Potassium (KCa) Channels
    Summary: Antiepileptic with anticonvulsant and mechanistic effect
      insoluble in H2O; ≥8.35 mg/mL
  3. TSU-68 (SU6668,Orantinib)
    A5331 TSU-68 (SU6668,Orantinib)
    Summary: PDGFR/Flk-1/FGFR1 inhibitor,potent and competitive
      insoluble in EtOH; insoluble in H2O; ≥15.5 mg/mL
  4. Venlafaxine
    A5355 Venlafaxine
    Summary: Dual serotonin/noradrenalin re-uptake inhibitor
      ≥28.65 mg/mL
  5. Alfuzosin HCl
    A5173 Alfuzosin HCl
    Summary: α1 adrenoceptor antagonist,functionally uro-selective
      ≥19 mg/mL
  6. Thiazovivin
    A5506 Thiazovivin
    Target: ROCK
    Summary: ROCK inhibitor
      ≥15.55 mg/mL
  7. Oligomycin A
    A5588 Oligomycin A
     1 Citation
    Target: Synthases/Synthetases
    Summary: Mitochondrial ATP synthase Inhibitor
  8. Sulfasalazine
    A5770 Sulfasalazine
    Summary: NF-κB activation inhibitor
      insoluble in ETOH; insoluble in H2O; ≥17.7 mg/mL
  9. Repaglinide
    A5316 Repaglinide
    Summary: Kir6 (KATP) channel blocker
  10. Febuxostat
    A5926 Febuxostat
    Summary: non-purine selective inhibitor of xanthine oxidase
      insoluble in H2O; ≥15.55 mg/mL

Items 501-510 of 9364

Page
per page